The STAR*D project results: A comprehensive review of findings

Overview of attention for article published in Current Psychiatry Reports, December 2007

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#36 of 1,306)
High Attention Score compared to outputs of the same age (99th percentile)

Mentioned by

news: 20 news outlets
blogs: 1 blog
policy: 1 policy source

twitter: 2 X users
patent: 32 patents
wikipedia: 2 Wikipedia pages

Citations

dimensions_citation: 550 Dimensions

Readers on

mendeley: 531 Mendeley
connotea: 1 Connotea

Summary News Blogs Policy documents X Patents Wikipedia Dimensions citations

So far, Altmetric has seen 26 news stories from 20 outlets.

MindBio Therapeutics Receives Final Regulatory Approval to Conduct Phase 2B Randomised Controlled Trial Microdosing Mb22001 in Patients Diagnosed with Major Depressive Disorder

Crwe World, 04 Mar 2024

Ethics and regulatory approvals finalized for world-first take-home use of a psychedelic medicine MB22001 in placebo-controlled…

MindBio Therapeutics Receives Final Regulatory Approval to Conduct Phase 2B Randomised Controlled Trial Microdosing Mb22001 in Patients Diagnosed with Major Depressive Disorder

Stockwatch, 04 Mar 2024

ORIGINAL: Ethics and regulatory approvals finalized for world-first take-home use of a psychedelic medicine MB22001 in placebo-co…

News story from Finanz Nachrichten on Monday 04 March 2024

Finanz Nachrichten, 04 Mar 2024

MindBio Therapeutics Receives Final Regulatory Approval to Conduct Phase 2B Randomised Controlled Trial Microdosing Mb22001 in Patients Diagnosed with Major Depressive Disorder

Yahoo! Finance USA, 04 Mar 2024

Ethics and regulatory approvals finalized for world-first take-home use of a psychedelic medicine MB22001 in placebo-controlled…

MindBio Therapeutics Receives Final Regulatory Approval to Conduct Phase 2B Randomised Controlled Trial Microdosing Mb22001 in Patients Diagnosed with Major Depressive Disorder

Le Lézard, 04 Mar 2024

Ethics and regulatory approvals finalized for world-first take-home use of a psychedelic medicine MB22001 in placebo-controlled…

MindBio Therapeutics Receives Final Regulatory Approval to Conduct Phase 2B Randomised Controlled Trial Microdosing Mb22001 in Patients Diagnosed with Major Depressive Disorder

benzinga, 04 Mar 2024

Ethics and regulatory approvals finalized for world-first take-home use of a psychedelic medicine MB22001 in placebo-controlled…

MindBio Therapeutics Receives Final Regulatory Approval to Conduct Phase 2B Randomised Controlled Trial Microdosing Mb22001 in Patients Diagnosed with Major Depressive Disorder

PharmiWeb, 04 Mar 2024

(the "" or "") is pleased to announce final regulatory approvals have been received for a world's first Phase 2B randomized…

Microdosing LSD For Major Depression Treatment Seeks Further Clinical Validation Via New Study

Benzinga, 24 May 2023

was granted approval by both the Ethics committee and the Clinical Trials Registry to begin the world's first Phase 2a take-home…

News story from Finanz Nachrichten on Tuesday 23 May 2023

Finanz Nachrichten, 23 May 2023

MindBio Therapeutics meldet die Genehmigung einer weltweit ersten klinischen Phase-2-Studie zur Heimanwendung einer LSD-Mikrodosierung bei schweren depressiven Störungen durch die Ethikkommission

Ariva, 23 May 2023

- Die klinische Studie wurde vom Register für klinische Studien (Clinical Trials Registry) genehmigt - Eine von zwei…

IRW-News: MindBio Therapeutics Corp. : MindBio Therapeutics meldet die Genehmigung einer weltwe [...]

Aktien Check, 23 May 2023

IRW-PRESS: MindBio Therapeutics Corp. : MindBio Therapeutics meldet die Genehmigung einer weltweit ersten klinischen Phase-2-Stud…

- Die klinische Studie wurde vom Register f?r klinische Studien (?Clinical Trials

Ad Hoc News, 23 May 2023

MindBio Therapeutics meldet die Genehmigung einer weltweit ersten klinischen Phase-2-Studie zur Heimanwendung einer LSD-Mikrodosi…

MindBio Therapeutics Corp. : MindBio Therapeutics meldet die Genehmigung einer weltweit ersten klinischen Phase-2-Studie zur Heimanwendung einer LSD-…

börsenNEWS.de, 23 May 2023

IRW-News: MindBio Therapeutics Corp. : MindBio Therapeutics meldet die Genehmigung einer weltweit ersten klinischen Phase-2-Studi…

IRW-News: MindBio Therapeutics Corp. : MindBio Therapeutics meldet die Genehmigung einer weltweit ersten klinischen Phase-2-Studie zur Heimanwendung einer LSD-Mikrodosierung bei schweren depressiven Störungen durch die Ethikkommission

Onvista, 23 May 2023

IRW-PRESS: MindBio Therapeutics Corp. : MindBio Therapeutics meldet die Genehmigung einer weltweit ersten klinischen Phase-2-Stud…

MindBio Therapeutics Ethics Approval for Landmark World First Phase 2 Clinical Trial of Take-Home LSD-Microdosing for Major Depressive Disorder

Morning Star, 23 May 2023

Ethics approval received for take-home LSD-Microdosing clinical trial in depressed patients Clinical trial has been approved by…

News story from Finanz Nachrichten on Tuesday 23 May 2023

Finanz Nachrichten, 23 May 2023

MindBio Therapeutics Ethics Approval for Landmark World First Phase 2 Clinical Trial of Take-Home LSD-Microdosing for Major Depressive Disorder

AP News, 23 May 2023

Ethics approval received for take-home LSD-Microdosing clinical trial in depressed patients Clinical trial has been approved by…

MindBio Therapeutics Ethics Approval for Landmark World First Phase 2 Clinical Trial of Take-Home LSD-Microdosing for Major Depressive Disorder

Le Lézard, 23 May 2023

/ MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), (the "Company" or "MindBio") is pleased to announce that ethics…

MindBio Therapeutics Ethics Approval for Landmark World First Phase 2 Clinical Trial of Take-Home LSD-Microdosing for Major Depressive Disorder

Benzinga, 23 May 2023

(the "" or "") is pleased to announce that ethics approval has been received for a world's first Phase 2a take home LSD-Microdosi…

MindBio Therapeutics Ethics Approval for Landmark World First Phase 2 Clinical Trial of Take-Home LSD-Microdosing for Major Depressive Disorder

Yahoo! Finance USA, 23 May 2023

Ethics approval received for take-home LSD-Microdosing clinical trial in depressed patients Clinical trial has been approved by…

MindBio Therapeutics Ethics Approval for Landmark World First Phase 2 Clinical Trial of Take-Home LSD-Microdosing for Major Depressive Disorder

Biospace, 23 May 2023

Ethics approval received for take-home LSD-Microdosing clinical trial in depressed patients Clinical trial has been approved by…

Can ketamine treat depression? I tried it.

Vox.com, 19 Feb 2019

I am going to die in this dentist’s chair. My eyes are closed, but I can still see skulls outlined with white against a black…

A fresh crop of promising drugs is poised to change the way depression is treated for the first time in decades. Here are the ones to watch in 2019.

Business Insider Singapore, 20 Dec 2018

Researchers are on the hunt for better drugs to treat depression, a leading cause of disability worldwide.

A fresh crop of promising drugs is poised to change the way depression is treated for the first time in decades. Here are the ones to watch in 2019.

Business Insider Australia , 20 Dec 2018

Researchers are on the hunt for better drugs to treat depression, a leading cause of disability worldwide.

A fresh crop of promising drugs is poised to change the way depression is treated for the first time in decades. Here are the ones to watch in 2019.

Business Insider India, 20 Dec 2018

Researchers are on the hunt for better drugs to treat depression, a leading cause of disability worldwide.

Can ketamine treat depression? I tried it.

Vox.com, 24 Jul 2018

I am going to die in this dentist’s chair. My eyes are closed, but I can still see skulls outlined with white against a black…